Evidence map›Paper›PMID 34249431›Full record

ArticleAmerican journal of cancer research2021

NONO phase separation enhances DNA damage repair by accelerating nuclear EGFR-induced DNA-PK activation.

Xin-Juan Fan, Yun-Long Wang, Wan-Wen Zhao, Shao-Mei Bai, Yan Ma, Xin-Ke Yin, Li-Li Feng, Wei-Xing Feng, Ying-Nai Wang, Quentin Liu and 2 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The metabolic enzyme GYS1 condenses with NONO/p54Cell death and differentiation · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Chromatin Perturbation Promotes Susceptibility to Hypomethylating Agents.bioRxiv : the preprint server for biology · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Xin-Juan FanGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou 510655, Guangdong, P. R. China.
Yun-Long WangGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou 510655, Guangdong, P. R. China.
Wan-Wen ZhaoGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou 510655, Guangdong, P. R. China.
Shao-Mei BaiDepartment of Radiation Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou 510655, Guangdong, P. R. China.
Yan MaDepartment of Radiation Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou 510655, Guangdong, P. R. China.
Xin-Ke YinGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou 510655, Guangdong, P. R. China.
Li-Li FengGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou 510655, Guangdong, P. R. China.
Wei-Xing FengDepartment of Radiation Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou 510655, Guangdong, P. R. China.
Ying-Nai WangDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston 77030, Texas, USA.
Quentin LiuInstitute of Cancer Stem Cell, Dalian Medical University Dalian 116044, Liaoning, P. R. China.
Mien-Chie HungDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston 77030, Texas, USA.
Xiang-Bo WanGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University Guangzhou 510655, Guangdong, P. R. China.
Asia University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioresistance is one of the main causes of cancer treatment failure, which leads to relapse and inferior survival outcome of cancer patients. Liquid-liquid phase separation (LLPS) of proteins is known to be involved in various biological processes, whereas its role in the regulation of radiosensitivity remains largely unknown. In this study, we characterized NONO, an RNA/DNA binding protein with LLPS capacity, as an essential regulator of tumor radioresistance. In vitro assay showed that NONO involved in DNA repair via non-homologous end joining (NHEJ) manner. NONO knockout significantly reduced DNA damage repair and sensitized tumor cells to irradiation in vitro and in vivo. NONO overexpression was correlated with an inferior survival outcome in cancer patients. Mechanically, NONO was associated with nuclear EGFR (nEGFR). Both irradiation and EGF treatment induced nEGFR accumulation, thereby increased the association between NONO and nEGFR. However, NONO was not a substrate of EGFR kinase. Furthermore, NONO promoted DNA damage-induced DNA-PK phosphorylation at T2609 by enhancing the interaction between EGFR and DNA-PK. Importantly, NONO protein formed high concentration LLPS droplets in vitro, and recruited EGFR and DNA-PK. Disruption of NONO droplets with LLPS inhibitor significantly reduced the interaction between EGFR and DNA-PK, and suppressed DNA damage-induced phosphorylation of T2609-DNA-PK. Taken together, LLPS of NONO recruits nuclear EGFR and DNA-PK and enhances their interaction, further increases DNA damage-activated pT2609-DNA-PK and promotes NHEJ-mediated DNA repair, finally leads to tumor radioresistance. NONO phase separation-mediated radioresistance may serve as a novel molecular target to sensitize tumor cell to radiotherapy.

Indexed as

DNA repairNONOnuclear EGFRPhase separationradioresistance

Identifiers

PMID34249431
PMCPMC8263645
OpenAlexW3179829393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.